TEVA logo

TEVA Accounts receivable

Annual accounts receivable:

$3.06B-$349.00M(-10.24%)
December 31, 2024

Summary

  • As of today (May 31, 2025), TEVA annual accounts receivable is $3.06 billion, with the most recent change of -$349.00 million (-10.24%) on December 31, 2024.
  • During the last 3 years, TEVA annual accounts receivable has fallen by -$1.47 billion (-32.46%).
  • TEVA annual accounts receivable is now -59.34% below its all-time high of $7.52 billion, reached on December 31, 2016.

Performance

TEVA Accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTEVAbalance sheet metrics

Quarterly accounts receivable:

$3.38B+$325.00M(+10.62%)
March 31, 2025

Summary

  • As of today (May 31, 2025), TEVA quarterly accounts receivable is $3.38 billion, with the most recent change of +$325.00 million (+10.62%) on March 31, 2025.
  • Over the past year, TEVA quarterly accounts receivable has dropped by -$72.00 million (-2.08%).
  • TEVA quarterly accounts receivable is now -58.07% below its all-time high of $8.07 billion, reached on September 30, 2016.

Performance

TEVA Quarterly accounts receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTEVAbalance sheet metrics

Accounts receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

TEVA Accounts receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-10.2%-2.1%
3 y3 years-32.5%-20.4%
5 y5 years-46.1%-34.8%

TEVA Accounts receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-32.5%at low-24.3%+10.6%
5 y5-year-46.1%at low-34.8%+10.6%
alltimeall time-59.3%+746.7%-58.1%+836.6%

TEVA Accounts receivable History

DateAnnualQuarterly
Mar 2025
-
$3.38B(+10.6%)
Dec 2024
$3.06B(-10.2%)
$3.06B(-11.6%)
Sep 2024
-
$3.46B(-8.1%)
Jun 2024
-
$3.77B(+9.0%)
Mar 2024
-
$3.46B(+1.4%)
Dec 2023
$3.41B(-7.8%)
$3.41B(+0.7%)
Sep 2023
-
$3.38B(-4.4%)
Jun 2023
-
$3.54B(+3.0%)
Mar 2023
-
$3.44B(-7.1%)
Dec 2022
$3.70B(-18.4%)
$3.70B(-0.9%)
Sep 2022
-
$3.73B(-16.6%)
Jun 2022
-
$4.47B(+5.1%)
Mar 2022
-
$4.25B(-6.1%)
Dec 2021
$4.53B(-1.1%)
$4.53B(+11.9%)
Sep 2021
-
$4.05B(-9.8%)
Jun 2021
-
$4.49B(-1.8%)
Mar 2021
-
$4.57B(-0.2%)
Dec 2020
$4.58B(-19.3%)
$4.58B(+4.5%)
Sep 2020
-
$4.38B(-3.5%)
Jun 2020
-
$4.54B(-12.4%)
Mar 2020
-
$5.19B(-8.6%)
Dec 2019
$5.68B(-2.5%)
$5.68B(+8.0%)
Sep 2019
-
$5.25B(-0.1%)
Jun 2019
-
$5.26B(+3.0%)
Mar 2019
-
$5.11B(-12.3%)
Dec 2018
$5.82B(-18.3%)
$5.82B(+2.8%)
Sep 2018
-
$5.67B(-6.5%)
Jun 2018
-
$6.06B(-3.6%)
Mar 2018
-
$6.29B(-11.8%)
Dec 2017
$7.13B(-5.3%)
$7.13B(-4.0%)
Sep 2017
-
$7.42B(+1.4%)
Jun 2017
-
$7.32B(+0.8%)
Mar 2017
-
$7.26B(-3.4%)
Dec 2016
$7.52B(+40.6%)
$7.52B(-6.8%)
Sep 2016
-
$8.07B(+50.2%)
Jun 2016
-
$5.37B(+3.6%)
Mar 2016
-
$5.19B(-3.0%)
Dec 2015
$5.35B(-1.1%)
$5.35B(+1.4%)
Sep 2015
-
$5.28B(-5.3%)
Jun 2015
-
$5.57B(+1.1%)
Mar 2015
-
$5.51B(+1.8%)
Dec 2014
$5.41B(+1.3%)
$5.41B(-0.0%)
Sep 2014
-
$5.41B(+0.4%)
Jun 2014
-
$5.39B(+2.2%)
Mar 2014
-
$5.28B(-1.2%)
Dec 2013
$5.34B(-4.2%)
$5.34B(+2.8%)
Sep 2013
-
$5.19B(-2.1%)
Jun 2013
-
$5.30B(-2.0%)
Mar 2013
-
$5.42B(-2.8%)
DateAnnualQuarterly
Dec 2012
$5.57B(-10.3%)
$5.57B(-3.6%)
Sep 2012
-
$5.78B(+6.5%)
Jun 2012
-
$5.43B(-10.3%)
Mar 2012
-
$6.06B(-2.5%)
Dec 2011
$6.21B(+13.5%)
$6.21B(+10.8%)
Sep 2011
-
$5.61B(+2.5%)
Jun 2011
-
$5.47B(-1.9%)
Mar 2011
-
$5.58B(+1.8%)
Dec 2010
$5.48B(+9.1%)
$5.48B(+4.7%)
Sep 2010
-
$5.23B(+4.9%)
Jun 2010
-
$4.99B(-2.9%)
Mar 2010
-
$5.14B(+2.3%)
Dec 2009
$5.02B(+7.9%)
$5.02B(+7.0%)
Sep 2009
-
$4.69B(+7.2%)
Jun 2009
-
$4.38B(+5.9%)
Mar 2009
-
$4.13B(-11.2%)
Dec 2008
$4.65B(+31.2%)
$4.65B(+18.8%)
Sep 2008
-
$3.92B(+3.5%)
Jun 2008
-
$3.78B(+5.1%)
Mar 2008
-
$3.60B(+1.5%)
Dec 2007
$3.55B(+21.4%)
$3.55B(+8.2%)
Sep 2007
-
$3.28B(+7.4%)
Jun 2007
-
$3.05B(+10.1%)
Mar 2007
-
$2.77B(-5.1%)
Dec 2006
$2.92B(+65.2%)
$2.92B(-21.0%)
Sep 2006
-
$3.70B(+3.2%)
Jun 2006
-
$3.58B(+66.2%)
Mar 2006
-
$2.16B(+21.9%)
Dec 2005
$1.77B(+19.9%)
$1.77B(+11.4%)
Sep 2005
-
$1.59B(+3.8%)
Jun 2005
-
$1.53B(-5.7%)
Mar 2005
-
$1.62B(+9.9%)
Dec 2004
$1.48B(+43.1%)
$1.48B(+6.0%)
Sep 2004
-
$1.39B(+6.8%)
Jun 2004
-
$1.30B(+6.8%)
Mar 2004
-
$1.22B(+18.2%)
Dec 2003
$1.03B(+20.6%)
$1.03B(+15.4%)
Sep 2003
-
$894.30M(+5.0%)
Jun 2003
-
$851.60M(+3.6%)
Mar 2003
-
$822.40M(-3.9%)
Dec 2002
$855.80M(+31.4%)
$855.80M(+23.1%)
Sep 2002
-
$695.40M(-0.1%)
Jun 2002
-
$696.10M(+8.2%)
Mar 2002
-
$643.10M(-1.2%)
Dec 2001
$651.19M(+19.8%)
$651.19M(+10.1%)
Sep 2001
-
$591.40M(-1.4%)
Jun 2001
-
$600.08M(+4.1%)
Mar 2001
-
$576.45M(+6.0%)
Dec 2000
$543.66M(+50.5%)
$543.66M(+50.5%)
Dec 1999
$361.29M
$361.29M

FAQ

  • What is Teva Pharmaceutical Industries Limited annual accounts receivable?
  • What is the all time high annual accounts receivable for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited annual accounts receivable year-on-year change?
  • What is Teva Pharmaceutical Industries Limited quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited quarterly accounts receivable year-on-year change?

What is Teva Pharmaceutical Industries Limited annual accounts receivable?

The current annual accounts receivable of TEVA is $3.06B

What is the all time high annual accounts receivable for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high annual accounts receivable is $7.52B

What is Teva Pharmaceutical Industries Limited annual accounts receivable year-on-year change?

Over the past year, TEVA annual accounts receivable has changed by -$349.00M (-10.24%)

What is Teva Pharmaceutical Industries Limited quarterly accounts receivable?

The current quarterly accounts receivable of TEVA is $3.38B

What is the all time high quarterly accounts receivable for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high quarterly accounts receivable is $8.07B

What is Teva Pharmaceutical Industries Limited quarterly accounts receivable year-on-year change?

Over the past year, TEVA quarterly accounts receivable has changed by -$72.00M (-2.08%)
On this page